OR WAIT null SECS
New Service Enables Combination Tumor Assessments using both RECIST and irRC
WorldCare Clinical, LLC (WCC), a CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced a new service that enables efficient capture and analysis of both standard tumor assessment, such as RECIST (Response Evaluation Criteria in Solid Tumors), and the newer immune-related response criteria (irRC) simultaneously. Developed in collaboration with leading academic researchers, WCC’s method has been validated and is being used to evaluate new immune-related treatments.
WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The new service was designed for sponsors developing immunotherapeutic agents who want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.
“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WorldCare Clinical. “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”
WCC Director of Software Engineering Patrick Chokron will present on the benefits of combining both tumor assessment approaches at the upcoming Immunomodulatory Therapeutic Antibodies for Cancer conference, August 13-15, 2013 in Boston. Chokron’s presentation, “Image Assessment in Immunotherapeutic Trials: Combining irRC and RECIST 1.1,” will take place at the Hilton Boston Back Bay Hotel on Thursday, August 15, 2013 at 12:00 p.m.
For more information on WCC’s services for oncology imaging studies, call (888) 816-4721 or visit www.wcclinical.com.